Literature DB >> 11964899

Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.

Patrick G Hoggard1, David J Back.   

Abstract

Antiretroviral agents target HIV replication within infected cells. It is therefore important to focus on the pharmacology of these drugs at their site of action rather than just in plasma. Activation of nucleoside analogues to a triphosphate is essential for antiretroviral activity. Following activation, by intracellular kinases, drug triphosphates compete with endogenous triphosphates for HIV reverse transcriptase. Methodologies to measure triphosphates in peripheral blood mononuclear cells from HIV patients have been described. This has allowed investigation of once-daily dosing regimens, drug interactions, modulation of intracellular activation and the bypassing of initial phosphorylation steps. Drug accumulation within a cell is a balance between influx and efflux. There is a growing body of evidence indicating that transport proteins are vitally important in regulating intracellular concentrations of antiretroviral drugs. Allelic variants, inhibition (or induction) are all potentially critical determinants of active drug present in the cell. It is hoped that understanding the intracellular pharmacology will improve long-term therapy and reduce the likelihood of cellular resistance in therapeutic failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964899     DOI: 10.1097/00001432-200202000-00002

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

Review 1.  Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Authors:  Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Chuan-Jen Wang; Wing Lam; Fang-Yong Li; Musie Ghebremichael; Veronika Northrup; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Sex differences in antiretroviral therapy-associated intolerance and adverse events.

Authors:  Rebecca Clark
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.

Authors:  N Jung; C Lehmann; A Rubbert; E Schömig; G Fätkenheuer; P Hartmann; D Taubert
Journal:  Infection       Date:  2012-08-09       Impact factor: 3.553

Review 5.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.

Authors:  Peter L Anderson; Tracy King; Jia-Hua Zheng; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2008-06-20       Impact factor: 5.790

7.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

Review 8.  Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models.

Authors:  Yanni Xiao; Hongyu Miao; Sanyi Tang; Hulin Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-04-17       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.